Please wait a minute...

中国生物工程杂志

CHINA BIOTECHNOLOGY
中国生物工程杂志  2011, Vol. 31 Issue (03): 29-34    
研究报告     
shRNA靶向干扰COX-2抑制人肝癌裸鼠皮下移植瘤及其血管生成
陈光辉1, 刘预2, 孔飞飞1, 邱欣欣1, 成凤1, 匡文斌1, 李朴1, 涂植光1
1. 重庆医科大学医学检验系 临床检验诊断学教育部重点实验室 重庆 400016;
2. 重庆市肿瘤医院临床检验中心 重庆 400030
Inhibitory Effects of Cyclooxygenase-2 Inhibited by shRNA on the Growth and Angiogenesis of Human Liver Cancer Cell Subcutaneous Xenograft Tumors in Nude Mice
CHEN Guang-hui1, LIU Yu2, KONG Fei-fei1, QIU Xin-xin1, CHENG Feng1, KUANG Wen-bin1, LI Pu1, TU Zhi-guang1
1. Key Laboratory of Laboratory Medical Diagnostics of Ministry of Education, Faculty of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, China;
2. Clinical Laboratory Center, Chongqing Tumor Hospital, Chongqing 400030, China
 全文: PDF(762 KB)   HTML
摘要:

目的:探讨重组干扰质粒pshRNA-COX-2对人肝癌细胞Hep3B裸鼠皮下移植瘤生长和肿瘤血管生成的抑制作用。方法:重组干扰质粒pshRNA-COX-2转染Hep3B细胞并筛选后,RT-PCR和Western blot检测COX-2mRNA和蛋白表达,RT-PCR检测VEGFmRNA表达。将被成功转染的Hep3B细胞种植于裸鼠皮下,测量肿瘤大小,4周后处死裸鼠,免疫组织化学法检测肿瘤组织中COX-2蛋白表达和肿瘤微血管密度(MVD)。结果:与未转染细胞相比,干扰组COX-2mRNA和蛋白表达抑制率分别为65.3%和52.8%(P<0.05),干扰组VEGFmRNA表达抑制率为56.5%(P<0.05)。干扰组瘤体大小明显小于阴性组和空白组(P<0.01)。干扰组COX-2得分和MVD均明显低于阴性组和空白组(P<0.01)。结论:pshRNA-COX-2通过抑制COX-2表达明显抑制人肝癌细胞Hep3B裸鼠皮下移植瘤生长和肿瘤血管生成。

关键词: 肝癌环氧化酶-2重组干扰质粒pshRNA-COX-2皮下移植瘤血管生成    
Abstract:

Objective: To investigate the inhibitory effects of recombinant interference plasmid pshRNA-COX-2 on the growth and angiogenesis of human liver cancer cell Hep3B subcutaneous xenograft tumors in nude mice. Methods: The COX-2 mRNA and protein expressions were measured by reverse transcription polymerase chain reaction (RT-PCR) and Western blot, the VEGF mRNA expression was detected by RT-PCR after Hep3B cells were transfected with plasmid pshRNA-COX-2 and selected. Selected Hep3B cells were transplanted into the subcutaneous tissue of nude mice. Xenograft tumor volume was measured every three days and growth curves of tumors were drawn. The mice were killed after four weeks. The expression of COX-2 protein and microvessel density (MVD) in xenograft tumors were observed by immunohistochemistry. Results: Compared to the Hep3B cells without transfected by plasmid pshRNA-COX-2, the inhibition rates of COX-2 mRNA and protein expressions were 65.3% and 52.8% respectively in the pshRNA-COX-2 group (P<0.05), the inhibition rate of VEGF mRNA expression was 56.5% in the pshRNA-COX-2 group (P<0.05). The tumor volume in the pshRNA-COX-2 group was apparently smaller than that of the pshRNA-HK group and the untreated group (P<0.01). The COX-2 score and MVD in the pshRNA-COX-2 group were significantly lower than that of the pshRNA-HK group and the untreated group (P<0.01). Conclusion: The plasmid pshRNA-COX-2 can significantly inhibit the growth and angiogenesis of human liver cancer cell Hep3B subcutaneous xenografts in nude mice through inhibiting COX-2 expression.

Key words: Human liver cancer    Cyclooxygenase-2    Recombinant interference plasmid pshRNA-COX-2    Subcutaneous xenograft tumor    Angiogenesis
收稿日期: 2010-11-17 出版日期: 2011-04-01
ZTFLH:  R735.7  
基金资助:

重庆市科委自然科学基金资助项目(2006BB5271)

通讯作者: 涂植光     E-mail: tuzhiguang@yahoo.com.cn
服务  
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章  
陈光辉
刘预
孔飞飞
邱欣欣
成凤
匡文斌
李朴
涂植光

引用本文:

陈光辉, 刘预, 孔飞飞, 邱欣欣, 成凤, 匡文斌, 李朴, 涂植光. shRNA靶向干扰COX-2抑制人肝癌裸鼠皮下移植瘤及其血管生成[J]. 中国生物工程杂志, 2011, 31(03): 29-34.

CHEN Guang-hui, LIU Yu, KONG Fei-fei, QIU Xin-xin, CHENG Feng, KUANG Wen-bin, LI Pu, TU Zhi-guang. Inhibitory Effects of Cyclooxygenase-2 Inhibited by shRNA on the Growth and Angiogenesis of Human Liver Cancer Cell Subcutaneous Xenograft Tumors in Nude Mice. China Biotechnology, 2011, 31(03): 29-34.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/        https://manu60.magtech.com.cn/biotech/CN/Y2011/V31/I03/29

[1] Bosch F X, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis, 1999, 19(3): 271-285.
[2] Thomas M B, Zhu A X. Hepatocellular carcinoma:the need for progress. J Clin Oncol, 2005, 23(13): 2892-2899.
[3] Cerveilo M, Foderaa D, Florena, et a1. Correlation between expression of cyelooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma:possible role in tumor promotion and angiogenesis. World J Gastroenterol, 2005, 11(30): 4638 -4643.
[4] Cervello M, Montalto G. Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol, 2006, 12(32): 5113-5121.
[5] Uefuji K, Ichikura T, Mochizuki H. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol, 2001, 76(1): 26-30.
[6] Zhang H, Sun X F. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer . Am J Gastroenterol, 2002, 97(4): 1037-1041.
[7] Parrett M L, Haltis R E, Joarder F S, et al. Cyclooxygenase-2 expression in human breast cancer . Int J Oncology, 1997, 10(7): 503-507.
[8] Dohmen K, Okabe H, Ishibashi H. Regression of hepatocellular carcinoma due to cyclooxygenase (COX)-2 inhibitor. Am J Gastroenterol, 2006, 101(10): 2437-2438.
[9] Strillaccit A, Griffoni C, Spisni E, et al. RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells . Briti J of Can, 2006, 94(9):1300-1310.
[10] Charames G S, Bapat B. Cyclooxygenese-2 knockdown by RNA interference in colon cancer . Int J Oncol, 2006, 28(2): 543-549.
[11] 杨义明,刘预,涂植光,等. 短发夹RNA抑制肝癌细胞HepG2 COX-2基因表达的探讨. 中国肿瘤临床, 2007, 34(10): 566-569. Yang Y M, Liu Y, Tu Z G, et al. Chinese Journal of Clinical Oncology, 2007, 34(10): 566-569.
[12] Soumaoro L T, Uetake H, Takagi Y, et a1. Coexpression of VEGF-C and COX-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum, 2006, 49(3): 392-398.
[13] von Rahden B H, Stein H J, Puhringer F, et a1. Coexpression of cyclooxygenases(COX-1, COX-2) and vascular endothelial growth factors(VEGF-A,VEGF-C) in esophageal adenocarcinoma. Cancer Res, 2005, 65(12): 5038-5044.
[14] Joo Y E, Rew J S, Seo Y H, et a1. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol, 2003, 37(1): 28-33.
[15] Timoshenko A V, Chakraborty C, Wagner G F, et al. Cox-2 mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Briti J Cancer 2006, 94(8): 1154-1163.
[16] Liu H, Yang Y, Xiao J, et al. COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer. Anat Rec, 2010, 293(11): 1838-1846.
[17] Kern M A, Schoneweiss M M, Sahi D, et al. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis,2004, 25(7): 1193-1199.
[18] Wang R, Wang X, Lin F, et al. shRNA-targeted Cyclooxygenase (COX)-2 inhibits proliferation, reduces invasion and enhances chemosensitivity in laryngeal carcinoma cells. Mol Cell Biochem, 2008, 317(1-2): 179-188.
[19] Narayanan B A, Narayanan N K, Davis L, et al. RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol Cancer Ther, 2006, 5(5): 1117-1125.

[1] 范梦恬, 陈思成, 郭杨柳, 李亚, 孙艳婷, 李汪, 施琼. 趋化因子受体CX3CR1对人肝癌细胞7721和HepG2的作用及其机制的研究[J]. 中国生物工程杂志, 2017, 37(6): 22-30.
[2] 谢琳娜,曾燕华,柯伙钊,何文胜,郑敏,林德馨. 在肝癌细胞SK-Hep1中沉默STAT3基因增强sorafenib疗效的初步研究*[J]. 中国生物工程杂志, 2017, 37(12): 8-13.
[3] 余琳,王建华,葛良鹏. 靶向Glypican-3的肝癌免疫治疗研究进展*[J]. 中国生物工程杂志, 2017, 37(12): 90-95.
[4] 曹荣月, 俞敏霞, 张昕黎, 李曼曼, 苗梓韬, 金亮. VEGFⅡ/GRP融合蛋白的构建、表达、纯化及其抗小鼠RM-1前列腺癌的作用研究[J]. 中国生物工程杂志, 2016, 36(8): 9-15.
[5] 张英敏, 赵娜, 李勇芳, 孟凡秀, 张琪, 高然朋, 张悦红, 于保锋, 郭睿, 王海龙, 解军, 徐钧. PBI-SUR-TK载体靶向介导HSV-TK自杀基因诱导肝癌细胞凋亡[J]. 中国生物工程杂志, 2016, 36(2): 16-21.
[6] 薛金锋, 薛志刚, 陈毅瑶, 李卓, 尹彪, 邬玲仟, 梁德生. 增强型肿瘤特异性启动子介导CDTK治疗肝癌的体内外研究[J]. 中国生物工程杂志, 2015, 35(6): 1-7.
[7] 叶雨辰, 赵俊龙, 王琳, 段娟丽, 高春辰, 秦鸿雁, 窦科峰. EGFP-Luc-Hepa1-6细胞系的构建及其在小鼠肝癌模型中的应用[J]. 中国生物工程杂志, 2015, 35(5): 1-7.
[8] 武睿, 周兰, 崔鲂. S100A9促进肝癌细胞HepG2的存活与侵袭依赖于RAGE[J]. 中国生物工程杂志, 2015, 35(5): 8-14.
[9] 付怀秀, 于翔, 康宏向, 梁洁, 陈鹏, 沈本剑, 金义光, 熊力, 毛建平. Photosan脂质立方液晶纳米光敏剂的制备及光动力杀伤效应研究[J]. 中国生物工程杂志, 2015, 35(3): 35-41.
[10] 孟树林, 马步云, 张新敏, 葛云, 张蓉, 黄盼盼, 王毅刚. 硫利达嗪对肝癌干细胞的杀伤作用研究[J]. 中国生物工程杂志, 2015, 35(2): 8-17.
[11] 赵晶, 吕慧, 贾依娜古丽·朱玛拜, 孙素荣. 骆驼蓬脂转移蛋白基因真核表达载体的构建及其体内外抗瘤效应的研究[J]. 中国生物工程杂志, 2014, 34(8): 7-13.
[12] 陈悦, 付中平, 李景荣, 殷晓进. 重组蛋白ES-Kringle5的表达、纯化及活性检测[J]. 中国生物工程杂志, 2014, 34(5): 60-65.
[13] 刘涛, 韩华锋, 马步云, 杨远勤, 卓玲燕, 周立, 王毅刚. 盐酸阿霉素增强溶瘤腺病毒ZD55-TRAIL抑制肝癌细胞生长的研究[J]. 中国生物工程杂志, 2014, 34(2): 26-33.
[14] 元小宁, 朱运峰. 外泌体(Exosome)及其在肿瘤调控中的作用[J]. 中国生物工程杂志, 2013, 33(8): 111-117.
[15] 季辉, 王琦, 仲蕾, 魏文祥. URI基因稳定表达对肝癌SMMC-7721细胞增殖能力的影响[J]. 中国生物工程杂志, 2013, 33(6): 1-6.